达格列净片致阴囊炎伴局部坏死1例分析

doi:10.19803/j.1672-8629.20250377

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (6): 690-692.
DOI: 10.19803/j.1672-8629.20250377

达格列净片致阴囊炎伴局部坏死1例分析

李化龙¹, 王凌峰¹, 卢倩²

¹巴彦淖尔市临河区人民医院药学部,内蒙古巴彦淖尔 015000;
²巴彦淖尔市临河区人民医院骨二科,内蒙古巴彦淖尔 015000

收稿日期:2025-06-16 出版日期:2026-06-15 发布日期:2026-06-18
作者简介:李化龙,男,本科,主管药师,呼吸临床药学。

One Case of Scrotal Inflammation with Local Necrosis Caused by Dapagliflozin Tablets

LI Hualong¹, WANG Lingfeng¹, LU Qian²

¹Department of Pharmacy, Linhe People’s Hospital of Bayannur, Bayannur Inner Mongolia 015000, China;
²Second Department of Orthopedics, Linhe People’s Hospital of Bayannur, Bayannur Inner Mongolia 015000, China

Received:2025-06-16 Online:2026-06-15 Published:2026-06-18

摘要/Abstract

摘要： 目的探讨达格列净致阴囊炎伴局部坏死的临床特征及治疗方法,为临床安全用药提供参考。方法结合国内外文献,对1例由达格列净致阴囊炎伴局部坏死的病例进行分析,并讨论其可能机制、临床特征及治疗。结果患者服用达格列净4个月后,出现阴囊附睾炎,查阅相关说明书、文献及判断用药时间关联性,判断患者阴囊炎伴局部坏死可能由达格列净引起,行右侧睾丸附睾切除术后患者出院。结论临床应用达格列净片时,需要注意泌尿生殖系统不良反应风险,如治疗不及时,可能导致手术或危及生命。

关键词: 达格列净, 阴囊炎, 局部坏死, 药品不良反应

Abstract: Objective To analyze the clinical characteristics and treatments of scrotal inflammation with local necrosis induced by dapagliflozin so as to provide a reference for safe clinical practice. Methods One case of scrotal inflammation with local necrosis induced by dapagliflozin was analyzed and the possible mechanism, clinical characteristics, and treatment regimens were investigated based on literature. Results After 4 months of taking dapagliflozin, the patient developed epididymo-orchitis. Related literature and time correlations of medication suggested that this symptom might have been caused by dapagliflozin. The patient was discharged after right testicular epididymis resection under intraspinal anesthesia. Conclusion When dapagliflozin is used in clinic, clinicians need to alert to adverse reactions in the urogenital system, which may lead to surgery or even threaten life if left untreated.

Key words: Dapagliflozin, Scrotal Inflammation, Local Necrosis, Adverse Drug Reactions

中图分类号:

R977
R994.11

李化龙, 王凌峰, 卢倩. 达格列净片致阴囊炎伴局部坏死1例分析[J]. 中国药物警戒, 2026, 23(6): 690-692.

LI Hualong, WANG Lingfeng, LU Qian. One Case of Scrotal Inflammation with Local Necrosis Caused by Dapagliflozin Tablets[J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 690-692.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250377

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I6/690

参考文献

[1] ZHUANG YR, XIE F, ZHU J, et al.Diabetic Ketoacidosis Induced by Dapagliflozin Complicated with Thyroid Storm:a Case Report[J]. Tianjin Pharmacy(天津药学), 2025, 37(4): 500-502.
[2] YU YY, ZHANG D.Diabetic Ketoacidosis Induced by Dapagliflozin: a Report of Two Cases and Literature Review[J]. Journal of Air Force Medical University(空军军医大学学报), 2024, 45(8): 958-960.
[3] ZHAO YH, YAN L, NING SS, et al.A Case Report of Urinary Tract Infection Caused by Taking Dapagliflozin[J]. The Medical Forum(基层医学论坛), 2023, 27(2): 12-15.
[4] CHEN AH, AO JF, LUO WY.Dapagliflozin-Induced Suspected Severe Skin Rash in 2 Cases[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2025, 45(8): 963-966.
[5] ZHAO R, ZHOU ZH, HANG YF, et al.Literature Case Analysis of 22 Patients with Acute Kidney Injury Induced by Sodium-Glucose Co-Transporter 2 Inhibitors[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2023, 43(16): 1846-1850.
[6] CHEN XY.Rare Instances of Acute Pancreatitis and Acute Liver Injury Induced by Dapagliflozin Tablets: one Case Report[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2024, 44(17): 2072-2074.
[7] PAN YP, WU SQ, WANG YL, et al.Medication Analysis and Pharma-ceutical Care of Urinary System Infection Caused by Dapagliflozin in a Patient with Heart Failure after Kidney Transplantation[J]. Practical Pharmacy And Clinical Remedies(实用药物与临床), 2024, 27(11): 855-858.
[8] CANG DX, SUN RN, QUAN XH, et al.Literature Case Analysis of Fournier Gangrene Caused by Sodium-Glucose Cotransporter 2 Inhibitors[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2025, 27(3): 147-152.
[9] ONDER CE, GURSOY K, KUSKONMAZ SM, et al.Fournier’s Gangrene in a Patient on Dapagliflozin Treatment for Type 2 Diabetes[J]. J Diabetes, 2019, 11(5): 348-350.
[10] RODLER S,WEIG T,FINKENZELLER C,et al.Fournier’s Gangrene under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: a Case Report and Review of the Literature[J]. Cureus, 2019, 11(9): e5778.
[11] GU HW, HAI X.Penis Ulceration and Candidal Balanitis Caused by Dapagliflozin: a Case Report[J]. Clinical Medication Journal(临床药物治疗杂志), 2022, 20(8): 86-88.
[12] NARANJO CA, BUSTO U, SELLERS EM, et al.A Method for Estimating the Probability of Adverse Drug Reactions[J]. Clinical Pharmacology and Therapeutics, 1981, 30(2): 239-245.
[13] WANG MS, ZHAO J, LI Y, Literature Analysis and Thinking of Adverse Drug Reactions Induced by Dapagliflozin[J]. Chinese General Practice(中国全科医学), 2020, 23(29): 3649-3654, 3666.
[14] XUE MY, LI X, KANG XH, et al.Discussion of Risk Factors and Prevent Measures for Urinary Tract Infection in Hospitalized Patients with Type 2 Diabetes Mellitus[J]. Progress in Modern Biomedicine(现代生物医学进展), 2022, 22(13): 2453-2457.
[15] DRYDEN M, BAGUNEID M, ECKMANN C, et al.Pathophysiology and Burden of Infection in Patients with Diabetes Mellitus and Peripheral Vascular Disease: Focus on Skin and Soft-Tissue Infections[J]. Clinical Microbiology and Infection: European Society of Clinical Microbiology and Infectious Diseases, 2015, 21(2): 27-32.

达格列净片致阴囊炎伴局部坏死1例分析

One Case of Scrotal Inflammation with Local Necrosis Caused by Dapagliflozin Tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	王春婷, 张瑞芳, 邓彬, 邹箴蕾, 王琨. 右旋糖酐铁注射液不良反应探析[J]. 中国药物警戒, 2026, 23(6): 672-676.
[2]	潘艳娟, 岳珂欣, 刘伟杰, 王领军, 王传升. 243例奥氮平不良反应报告分析[J]. 中国药物警戒, 2026, 23(6): 677-680.
[3]	王雨婷, 吕欣鸽, 潘晨, 武一, 崔向丽. 免疫检查点抑制剂致相关肠炎不良反应报告分析[J]. 中国药物警戒, 2026, 23(6): 681-685.
[4]	文冉苗, 陈悦, 杨彩华. 围产期盐酸克林霉素注射液致急性泛发性发疹性脓疱病2例分析[J]. 中国药物警戒, 2026, 23(6): 686-689.
[5]	兰芝荟, 卜丽佳, 宁洁, 江洁美, 杨彦彪. 注射用卡瑞利珠单抗致自身免疫性溶血性贫血1例分析[J]. 中国药物警戒, 2026, 23(6): 696-698.
[6]	王浩, 潘澎, 秦海军, 王建平. 肤痔清软膏致下肢水肿1例分析[J]. 中国药物警戒, 2026, 23(6): 699-701.
[7]	刘影, 薛红委, 庞楠, 杨中一, 柯文缘, 刘玲. 445例贝伐珠单抗注射液严重不良反应报告分析[J]. 中国药物警戒, 2026, 23(5): 547-552.
[8]	杜妍, 杨春兰, 孙旭群, 方玲. 121例PD-1/PD-L1抑制剂不良反应报告分析[J]. 中国药物警戒, 2026, 23(5): 553-557.
[9]	李兴桥, 马思佳. 基于真实世界数据的他汀类药品不良反应信号分析[J]. 中国药物警戒, 2026, 23(5): 558-563.
[10]	魏伟, 权勤波, 王玲华, 田月洁, 黄琳, 李娜, 王维波. 以某中药制剂为实证的真实世界药品不良反应可视化研究[J]. 中国药物警戒, 2026, 23(5): 564-568.
[11]	邹蕊, 吴雨桐, 周玥, 李琴, 孟召友. 特瑞普利单抗注射液致免疫检查点抑制剂相关重症肌无力合并急性心肌炎1例分析[J]. 中国药物警戒, 2026, 23(5): 569-571.
[12]	汤柳, 李洋, 罗广文, 鲍引娣. 利奈唑胺注射液致药物性肝损伤1例分析[J]. 中国药物警戒, 2026, 23(5): 572-574.
[13]	戴彪, 张松, 邓逸芸, 曹银, 张元元, 李培培, 梁俊. 硫普罗宁肠溶胶囊致粒细胞缺乏症1例分析[J]. 中国药物警戒, 2026, 23(5): 575-577.
[14]	王阿明, 魏筱, 吴慧, 张琳琳, 杨莉. 普瑞巴林胶囊致急性肝损伤1例分析[J]. 中国药物警戒, 2026, 23(5): 578-580.
[15]	张琴, 郑晓媛. 度普利尤单抗注射液致关节疼痛与肌无力1例分析[J]. 中国药物警戒, 2026, 23(5): 581-584.